FOREVER LIFE Trademark Cancellation Proceeding

The USPTO Trademark Trial and Appeal Board issued a decision in cancellation proceeding TTAB92089373 regarding the FOREVER LIFE trademark. Plaintiff Everlife LLC seeks cancellation of the mark owned by defendant TP International Inc. The TTAB granted a motion to suspend proceedings with consent pending settlement negotiations between the parties.

TTAB Cancellation: KALIFORNIA DYNAMIC

The USPTO Trademark Trial and Appeal Board (TTAB) issued a procedural order in Cancellation No. 92089396 suspending the proceeding pending disposition of an outstanding motion. The cancellation action was filed by Henry Goldansky against Kalifornia Dynamic LLC concerning the trademark KALIFORNIA DYNAMIC. The abstract indicates the Board has not yet reached a substantive determination on the merits of the cancellation claim.

Embecta Corp cancels Strive Medtech trademark

The USPTO Trademark Trial and Appeal Board (TTAB) granted Cancellation No. 92089505 filed by Embecta Corp against Strive Orthopedics, Inc., cancelling the STRIVE MEDTECH trademark registration. The cancellation was issued on April 6, 2026, with a refund issued under Trademark Rule 2.114(a)(2). Strive Orthopedics must cease all use of the STRIVE MEDTECH mark effective immediately.

WILD GALILEO trademark cancelled, Gynex beats imed

The USPTO Trademark Trial and Appeal Board granted Cancellation No. TTAB92090000, cancelling the WILD GALILEO trademark registration owned by imed medical GmbH. Gynex Corporation filed the cancellation proceeding on November 5, 2025, and obtained a favorable decision on April 6, 2026. The defendant must cease use of the WILD GALILEO mark and may no longer assert trademark rights in that designation.

Anti-opioid mAb patent, University of Minnesota, 7th Apr

The USPTO granted patent US12594330B2 to the Regents of the University of Minnesota covering opioid-specific monoclonal antibodies (mAbs), methods of manufacturing those antibodies, and therapeutic uses. The patent claims cover treatment of opioid use disorder, neonatal opioid withdrawal syndrome, and opioid overdose prevention and reversal. The invention also extends to detection of opioids in screening, diagnostic, or forensic assays.

Methods of treating psoriasis with secukinumab

The USPTO granted Patent US12594331B2 to Novartis AG on April 7, 2026, covering methods of treating psoriasis using secukinumab, an IL-17 antagonist antibody. The patent contains 16 claims directed to therapeutic regimens employing the drug for psoriasis treatment. This grant provides Novartis with exclusive intellectual property rights over this specific treatment methodology in the United States.

Platinum-based drug/photosensitizer-loaded protein nanoparticle patent granted to Soochow University

USPTO granted patent US12594335B2 to Soochow University on April 7, 2026, covering platinum-based drug/photosensitizer-loaded protein nanoparticles for combined chemotherapy and photodynamic tumor treatment. The invention includes 6 claims for nanoparticles with platinum-based drugs and photosensitizers encapsulated in protein carriers. Filing date was July 24, 2020, with application number 18012295.

Human Serum Albumin in Formulations

USPTO granted patent US12594337B2 to Regeneron Pharmaceuticals, Inc. covering human serum albumin formulations for reducing fatty acid particle formation in drug products, particularly antibody drug formulations. The patent contains 14 claims and was filed December 30, 2021.

Lipid nanoparticle delivery compositions for therapeutic agents

USPTO granted ModernaTX patent US12595226B2 for novel lipid nanoparticles and compositions for intracellular delivery of therapeutic agents. The patent covers carbonate-containing lipid compounds and compositions for delivering therapeutic and prophylactic agents such as RNA to mammalian cells. The patent contains 25 claims and names five inventors.

Lamotrigine hydrate crystal form, preparation method, and composition

The USPTO granted Patent US12595237B2 to Shanghai Aucta Pharmaceuticals Co., Ltd. for a crystalline form of lamotrigine hydrate (Form A), its method of preparation, and pharmaceutical compositions containing it. The patent contains 13 claims and is classified under CPC code A61K 31/53, covering the specific solid-state form of this antiepileptic drug compound.